US Orphan Drug Clinical Pipeline Investigated in New Cutting-edge PNS Pharma Report Published at MarketPublishers.com
25 Aug 2014 • by Natalie Aster
LONDON – Rare (orphan) diseases are generally categorized as life-threatening, degenerative and chronic in nature, and normally include metabolic conditions, certain disorders, musculoskeletal disorders and diseases of the nervous system, etc. Currently, the orphan drugs call for considerable competitive advantage due to the market exclusivity period after the authorization of drugs.
As of the US, the research and development of orphan drugs is supported by favourable government policies and regulations as well as public programs. The key incentives for R&D of orphan drugs include, among others, research support, grants, tax incentives, fee waivers and orphan drug market exclusivity. Moreover, in a highly specialized market such as that of orphan drugs, although the influence of market exclusivity in the country has been positive yet rather modest, a special platform for stable orphan drug development has been established by public support mechanisms and economic incentives.
The US orphan drugs market was evaluated at around USD 49 billion in 2013. The country’s orphan drugs market is poised for sustainable growth spurred by various factors like high profitability and government support, and many others. The US orphan drugs market is forecast to exceed USD 60 billion by 2018.
New research report “US Orphan Drug Clinical Pipeline Insight 2014” prepared by PNS Pharma gives a detailed analysis of the national orphan drug clinical pipeline. It contains a comprehensive assessment of the US orphan drug clinical pipeline by company, indication and phase. The topical study provides an all-round guide to the US orphan drugs market, offers a clear description of the regulative environment and also presents valuable profiles of marketed orphan drugs. It reviews orphan drugs in various stages of development, delves deep into the competitive scenario and unveils data on the top companies.
US Orphan Drug Clinical Pipeline Insight 2014
Published: August, 2014
Price: US$ 2,000.00
Other Recent Drug Pipelines Analyses by PNS Pharma:
- Cancer Cytokines Therapy Pipeline Analysis
- Schizophrenia Drug Market & Pipeline Insight
- Cervical Cancer Drug Market & Pipeline Insight
- Human Papillomavirus Infections Vaccine Pipeline Analysis
More new market research reports by the publisher can be found at PNS Pharma page.